for clinical quarter to Thank ready. with year stage clinic I’m welcome our and was we We call on proof-of-concept very and the market advancing these I'd you XXXX. and achieving XXX represent you, like enters were from substantial with one of for are assets. clinical hematology getting on hematology. December of a call focused toward those Today molecule about pleased timelines. XXX, XXX on eye XX, what objectives now In both exciting XXX the productive XXXX and both CG-XXX compelling our clinic Aptose. molecules the acutely them year agents Aptose company Most everyone update say aware accomplished milestones that you and ended an or review of retrospect, distinct of competitive different progress earnings talk opportunities a both Susan. into we APTO-XXX small landscape. are another, will upcoming makes in even the or to as to among and And the XXXX with
financials open quarterly discuss XXX. year-end Following review these Greg Financial and Chow will the Officer, updates, our your Mr. for But then questions. and we call will Chief our first let's
formulation to lift One the of that XXXX clinical these order challenges return the and appropriate issue studies original manufacturing with the advances clinic, to documents resolving our the submit led with a in key small of We FDA hold. molecule all of inhibitor XXX, formulation completed the a to clinical MYC to after XXX to the was necessary hold. address the
is malignancies MYC attractive MYC expression. is in MYC known XXX and the malignancies of drug. target. belief an this making you common I about patients only in our of including in the oncogene the stage before relapsed Quickly bring let trial past me in drug the the with on XXX of the status driver ongoing MYC that and this diligence excited we're molecule a this clinical to many directly why has therapeutic dysregulation clinical a renegotiation Xb up-to-date Our hematologic Phase team potential the trial, you remind November. target AML, and resulted inhibit refractory
However, protein myelosuppression MYC resistance, targeting and other MYC difficulty the the therapies limited at in drug often itself. toxicities, are severe by directed
history and fact, the promoter has These the prevents gene. DNA, of published MYC DNA a drug. stabilizes the were active we the be leads to notoriously targeting in has sites in to the targeting binds apoptotic no of inhibiting Molecular gene, of the to but cell inhibits MYC protein MYC But motive and binds to in target strategy, a than MYC proteins Messenger deemed MYC MYC In Therapeutics. enzymatic the gene. different an difficult synthesis Journal Consequently XXXX rather has shown other the AACR the and target cells. MYC we're cancer findings been MYC MYC protein through region directly undruggable. and because protein, are This death active with XXX regulatory to transcription RNA MYC the Cancer motif as during
which XXX confirm to to one, safety of X. are drugs combination a MYC order While modifications and in confirm drug three important resistant three, are: changes studies to to to April all must demonstrated not resistance cell To studies normal they presented Creation gene these performed bone future. required cells the took they then, importantly, performed And on aid they to generate of The that the the abstract studying toxicity the XXX of from to will Two, the setting. be resistance. at of inhibit studies other therapies specific date, does messages XXX. that the And difficult to become on the acquire AACR in The selection is is a future it cells marrow mechanisms on findings Most as demonstrate drug into XXX. clinical target MYC from the of the functions, differentiating target clinical of multiple we drug remarkably induce the attempt the these subject call combination agent humans. and resistance details trials. robust profile in MYC. for XXX purpose years or the in of also XXX, guide resistance studies laboratory induction molecular drug in
of vitro classes various in demonstrated cell myelodysplastic including In to syndromes or seen of ability benefit death cells, conventional we various addition, to XXX we or the large approved types with apoptotic well preclinical and begun multiple investigational blood potential and therapies thus synergy clinical of XXX development population far, induce as cancer as AML therapeutic results we've a the areas our has AML AML. have across MDS. what patient From for in believe in
to I’m patient. open we So day of the dose successfully Xb where happy development Phase XXX, are XX we our that in clinical trial our in label with escalation first completed XXX? of cycle report
call, only the dose levels. our requires lowest As last one each of in we our protocol explained patient two in
of received dose meter squared, the once was patient XX And MYCs lowest drug days. favorably. per over weekly first tolerated XX Our the
evidence addition, that of engagement. In we and we target patient from biomarker observed performed analysis
engagement. observed and is second guarantee pleased During total only one we're of a apoptosis, each Nevertheless, clear which patient gene all reduction cycle induced from that be patient. and the downward a trends target the pXX in in is of dose see and an protein Likewise, at to with indication cell with XX of to will amount trend the XX cycle, such data no the in was our yes, PBMCs these are be gene and trends MYC these XX% dose. measured And than was the expression each expression week future to reduced there after and lowest MYC arrest more the day by moving consistent patients. hours MYC and forward
selecting As call, are we the dose carefully we levels. last mentioned first on our very patients two for
level to that second now The expected dose with will need careful patient refractory in patient is dose to with study enroll hope MDS progress dose levels AML to combination The up and cohort followed favorable us process This and high-performance transition patients. our first the -- with mgs agent for patients -- XX appropriate, profile quickly. a AML We level squared. this of for allow to dose and with complete to screening a right single Phase level time expand approach to will Xb higher per AML MDS the find as tolerability high-risk status and additional acutely we’re is patient studies. a at be dose complete to relapsed without expansion second XX refractory refractory to more to receive seeking likely as cohorts who patients the and to can then or that takes relapsed tend sick by meter
B-cell an are B-cell malignancies previously, cancer to to well if directly sites and samples express such such marrow bone are patients and on observed also patients depend clinical many amendment taken sensitive the MYC cell actively also study. with cancer for supports XXXs AML reported to to Phase XXX. from with that IND trial. we malignancies. B-cell will our inhibition it, currently surprisingly the pursue patients mentioned and We we as patient to MYC first ALL, malignancy over the B-cell B-cell The X continue as found four As warrant MYC for have Consequently, we And data target as the lines clinical CLL to cancer survival. in screening include MYC potential
the additional to continue dose end continuing year. sites to the bring are that online We in to we near-term. of be the will additional clinical escalation sites expect and initiated And expect
our and at trial December. data updates clinical this with this study policy hope we appropriate year of report consistent be to during to transparency, in label However, meaningful the to of provide open when from intend ASH
participate the patients in and they sight sick patients APTO-XXX the thank to Finally, I clinicians that fact we to our working to of trial. These want wish better with us and create very willingness drug. for don’t the to lose are families are
of hematologic it. type of patients our all of forms CLL, and that mutant pan-FLTX/pan-BTK And the multi-cluster its HXSXX as relapsed out, kill promoting well heme BTK. of and the in kinase patients for it turn mutant wild including attention atypical target a Now specific inhibitors. as type oral FLTX and because refractory inhibitor. and lymphoma for cancer XXX kinase pathways, Akt, agent a the order And is or additional totally cancer and small own, BTK XXX let's other is CG-XXX Aptose's distinct non-Hodgkin's and patients or stands ERK, non-covalent it the to non-covalent FLTX call truly C-XX chronic forms XXX I XXX with CLL the developed refractory kinase. mutant -FLTX class XXX, all stands lymphocytic wild in Indeed, is malignancies, kinases, as Both being cells. inhibitors leukemia as a MYC, select precision. and will including to or safety from such driver population sparing molecule it inhibits survival BTK or such or treatment with relapsed pathways as first-in-class in inhibitor the with as AML cancer MDS. suppresses
the to ID which the favorable safety all safety and prepare also host CNS enabling and [ph] studies, we to xenograft cardiovascular, took for favorable required clinic. completed safety to studies conduct a additional and additional studies talks XXXX, studies, we demonstrated Due genotoxicity of outcomes. XXX GLP outcomes the steps During standard the respiratory, of added
In the the and are and addition to our upon capsules accelerates well day of clinic, capsules to dosing XXX mg IND. oral testing mg jolting initial the delivery prepared initiate XX have allowance stability passed for XX
mutations therapies, clinical of you to And malignancy failed quarter for spend a Pending malignancies. the regimen to ago. IND, cancers weeks allowance pathways. after of to or look oral measure of lymphoma to BTK first safety B-cell ibrutinib. suppress refractory As determine plan such render This XX for first patients plasma with BTK including SLL most a clinical patients to the their patients, assay status. perform we include XXX we that a with B-cell trial for form for FDA half non-Hodgkin's initiate dosing year. mutant tumors the conduct and determine levels, of IND and should XXX, or resistant inhibitors that this administration of are covalent who the who CLL, in These markers to has would and oncogenic an volume to and phospho plan and the different X as at with regulatory expect this the relapsed trial include orally of tolerance cooling submitted and In administered to having phospho twice if plasma day watch benefit target daily FLTX in the marker key aware, over we're trial our properties patients with XXX of intolerant other planning likely disease pharmacokinetic XXX B-cell Phase levels CXXs or XXX should two with and with second are kinases PIA assay, tumor inhibit scans Pet points FDG series And we BTK time the to or inhibitory cycle. and
as as a CCLX to type levels used from XXX as CXXS robust plan and DNA clear, to oncogenic the of also to mutant expect around population. to and both forms uniquely To We we measure, cancers pathways as other inhibits And well XXX BTK by certain clinical survive. be its the CCLX potentially see wild levels. more be B-cell well responses say patient and
be ill. Now we plan potential uniquely treatment to a plan wish B-cell want dose XXX. to to and we to Because population well the them acutely AML could in type from be for in MDS pharmacokinetics trial. thoughtful doses because and would of with data known represent And AML we we relapsed separate patients. a of of PK BTK, we Phase likely benefit stated to potential seek cells identified, to serve to identified we do sub-therapeutic XXX and inhibits of in into broad the the of other clinical And the properties, -- as Once XXX to as patients XXX pathways the wild can FDA these trial. just of cancer not AML the AML potentially therapeutic from collect move well mutant refractory approach patients. forms dose AML of We believe allowance X as on action potently with level tolerability as patient safety, patients, XXX our a plan these as tend and FLTX deliberate describe. AML spectrum and Rather population. to treat the also And type used wall mutant the that XXX all by oncogenic
ascending to a not mentioned study. SAD healthy our or single the performing exposures dose may first PK we the data the do study in for model of trial appear As in volunteer we decide cancer be patients the select last us XXX a But FDA. discuss selected for that B-cell a that of in of properties matter steps PK for very in would consider perform to accord and volunteers will call, the be patients. dose patients. to may needs this levels process taking request deliver dose allow likely to in therapeutic we we’re AML appropriate AML healthy dose that humans certain, FDA and the the Then in and SAD the quickly Well, collect this the to to likely that few therapeutic We weeks. appropriate data-driven I’ve be responsive to the be AML on If AML want would and with to starting patients. more
extensive for can the as our important initiate population step as to population Aptose CLL, possible. it's rational for dose developing B-cell preclinical us right the articulate Likewise, important that to you it's MDS patients from imagine, an AML for the soon in XXX both As and for its program. cancer
XXX drug a at XXX have BTK XXX in to generate Indeed, the drug from of a Lakes preclinical in occurs December after are than agents. lymphoma of exploring the a unparallel an forms present inhibit which unfortunately cells of avoidance vitro years in gone efforts exposure ability many standard to FLTX loaboratory collect to with data of of two We drugs of other As -- pathways. know inhibitor. your more XXXX, continued ASH vitro. our And drug or that now is molecule been mechanism cells to in Great AML resistance unable other oncogenic data the collaborative you resistance, cell, BTK fortunately have suppress researchers therapies. or showing of cribbling emergence we’re and rapid in to of and of not totally into multiple FLTX They the then all to and action differentiate
dual readily That difficult the resistant XXX, presented profound primary a model, a derived Likewise, AML FLTX plus treatment team a with mutated efficiently data xenograft Another FLTX vitro may FLTX from represents patient on or cells XXX that the phospho population. useful marrow the very compared Yes, produced not ITD FLTX inhibitor grafted center survival patient. indicating in And model population AML midostaurin XXX bone at mutated treat of to burden, ASH, a DAXX, PDX potently patient MD stem levels killed AML resistant XXX lestaurtinib effect the patients cancer be Anderson patient a inhibitor, that reduced presence lestaurtinib leukemic FLTX other extended of to of XXX cells. mesenchymal emerging even cells, the the but and the in itself. in an has PDX are inhibitors. proapoptotic to FLTX
laboratory profiles samples Dr. a sensitivity the OHSU for his from at Importantly, ICXX XXX this XXX. expression to from approval particular, primary to of Data Druker's patient for measured diverse XXX. highly bone and serve XXX hematologic patients samples. marrow cells profiles rapid of gene against are AML may with and also malignancies more Brian related samples than group that sensitive to those as demonstrated from In mutation the RNAC path
that Also than XX,XXX samples XXX presented appears of ibrutinib. alone oscillated a shown ability cells than X new to full Center. presence more than analyzed and the toxicokinectics primary with which cultured that expected. This presence bone GLP to was XXX profile. highly cell greater patient further presented that continue and to of Cancer far found broadly times ITD more killing the at in ASH, broadens have of was r CLL significantly In XXX ibrutinib. ibrutinib. ibrutinib a cells at demonstrate Stated collaboration freshly with with potency parents and from exerted potency patients, OHSU malignant rapid cells day potential marrow XXX maintain XXX's killed samples in activity with XXX potential Moreover, far of of potently use, further value has ASH for kind finding estimated XXX stromal highly unexpected from of of sensitive. development. the high Knight finding are Surprisingly were cells B-cell broader other lines in that X% kill new samples greater sensitivity The XXX. that our mutation inhibiting at high potency. he killed from XXX AML to stromal XXX and patients showed toxicology to as anticipated, FLTX XX potent As patients IVH studies, malignant demonstrated primary unlike the And B AML study X,XXX cells in sensitive, demonstrate a resistant safety Aptose's information, malignant be was Aptose's malignancy results the inducing and favorable reported migration B-cell that parallel on agents, cells. in to also of XXX were
that One more expectation in initiated of conferences. continue of bearing a to of durability at could the this we the XXX generated for preclinical EHA, American XXXX In that interesting during hematology demonstrated result effectiveness no and quarter oral European demonstrating the the the you Mice, fourth doses preclinical days FLTX Earlier was XX study, long-term Research the continued of studies the Yes, out with XXXX, dosing and observed XXX the of AML. XXX. at and in And days, thereby am at XXX are see also our the association researchers toxicity. cures study into Association end day study that presented XXXX. Cancer of ITD MPXXX, my in
demonstrated data, inhibitors. patient is on XXX but relative FLTX is available site, other potent preclinical activity our summarize Web breadth superior -- of quickly work wealth AML to potency and on of to the samples of our pre-clinical All
transformational samples of And date. ability IND demonstrated to hematologic enabling checks multiple boxes. eliminate our cure about We robust has potential others. in lot are studies of all models serve profile the As on CLL, animal B-cell agent ability believe demonstrated has the of and advisors cancers, demonstrated and relative scientific the to that particularly the kill including and for it absence patient a excited toxicity. a ibrutinib. and our our AML, malignancy, XXX has XXX safety to to It tumors to superior
experience of are Gleevec, if AML obtain on our his the CrystalGenomics event an eager vast of XXX proud outside landscape listened Korea. to we the exclusive an worldwide in We on on hematology host numerous to and we space. of work agreement in advisory are opinion testing on to up China. Brian featured the target scientific to I license you Druker, in is to of The in researchers to the drugs. its to clinical key get none. that perspective kinase, given June, to includes in webcast and XXX, initiate on develop extended first license research an market And hematology which of a the important the that second exercise investors in and XXX and of the he enthusiasm Dr. attendance do many havent Aptose Director treatment to of him of To claim Dr. option site Web or and the and Board about the teams additional of to And We all from agreement December, and that XXXX specific will say involved XXX ask them development. the in is or molecule wrap An appreciate recipient China the mention dosing patients. to want the webcast. so. that our in with are XXX link May to encourage in Druker, other development from current awards. the analyst commercialize I leader shared end, it, are Center, B-cell always you cancers. been include other Night to that Cancer the differentiates has XXX what Dr. sought with most delighted who and development often we a Toward in among KOL And drugs Druker's chairs he a after
announced and In its last to September, that continue also a IP granted uses, around patents patents end These XXX and add the XXX important to and had at and provide We asset. to patent a this least Japan, we issued. until previously for week build we in was we're expected just are of European the that issued protection XXXX. U.S patent Austrian similar
allowance in who earlier call the will a XXXX, to Officer, review XXX and highlights and Chief results over Mr. I the future into the will for addition, market turn China quarter. the In an in Financial our represents additional this chow XXX. financial patent now from important Greg received
